HomeAI · summaries
Storia in 3 fonti
ResMed Analyst Backs Portfolio Reset - ResMed (NYSE:RMD)
ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
afr.com
Resmed sells US software business on the cheap as AI threat looms
The medical device maker has sold the MatrixCare business for less than it bought it for eight years ago, with analysts pointing to potential AI disruption.
- ·
thenextweb.com
ResMed sells its MatrixCare software business to Frazier for $490m
ResMed is selling its MatrixCare home-health software unit to Frazier Healthcare Partners for $490m in cash to focus on sleep and breathing care.
